INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
USA - NASDAQ:IART - US4579852082 - Common Stock
11.35 USD
+0.2 (+1.79%)
Taking everything into account, IART scores 4 out of 10 in our fundamental rating. IART was compared to 188 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IART while its profitability can be described as average. IART has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
In the past year IART had a positive cash flow from operations.
IART had positive earnings in 4 of the past 5 years.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART has a Return On Assets (-13.58%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -47.74%, IART is in line with its industry, outperforming 51.60% of the companies in the same industry.
The Return On Invested Capital of IART (4.27%) is better than 73.94% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 8.98%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
With a decent Operating Margin value of 10.22%, IART is doing good in the industry, outperforming 77.13% of the companies in the same industry.
In the last couple of years the Operating Margin of IART has declined.
IART has a Gross Margin of 57.21%. This is comparable to the rest of the industry: IART outperforms 55.85% of its industry peers.
IART's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
IART has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, IART has less shares outstanding
Compared to 5 years ago, IART has less shares outstanding
IART has a worse debt/assets ratio than last year.
2.2 Solvency
IART has an Altman-Z score of 1.22. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
IART has a Altman-Z score of 1.22. This is comparable to the rest of the industry: IART outperforms 54.26% of its industry peers.
A Debt/Equity ratio of 1.73 is on the high side and indicates that IART has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.73, IART is doing worse than 81.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.22 |
ROIC/WACC0.83
WACC5.15%
2.3 Liquidity
IART has a Current Ratio of 3.14. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
IART's Current ratio of 3.14 is in line compared to the rest of the industry. IART outperforms 59.57% of its industry peers.
IART has a Quick Ratio of 1.80. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IART (1.80) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
Looking at the last year, IART shows a small growth in Revenue. The Revenue has grown by 4.99% in the last year.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 1.20% on average per year.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
The Earnings Per Share is expected to grow by 2.68% on average over the next years.
The Revenue is expected to grow by 2.39% on average over the next years.
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IART is valuated cheaply with a Price/Earnings ratio of 4.79.
Based on the Price/Earnings ratio, IART is valued cheaper than 97.87% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.47, IART is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 4.69, the valuation of IART can be described as very cheap.
IART's Price/Forward Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 99.47% of the companies in the same industry.
IART's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.79 | ||
| Fwd PE | 4.69 |
4.2 Price Multiples
93.62% of the companies in the same industry are more expensive than IART, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.52 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IART (11/20/2025, 12:06:44 PM)
11.35
+0.2 (+1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.73%
Inst Owner Change0.01%
Ins Owners3.04%
Ins Owner Change0.07%
Market Cap884.28M
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target17.34 (52.78%)
Short Float %10.31%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)3.48%
PT rev (3m)3.48%
EPS NQ rev (1m)-11.49%
EPS NQ rev (3m)-11.49%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)-5.75%
Revenue NQ rev (3m)-5.75%
Revenue NY rev (1m)-2.11%
Revenue NY rev (3m)-1.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.79 | ||
| Fwd PE | 4.69 | ||
| P/S | 0.54 | ||
| P/FCF | N/A | ||
| P/OCF | 9.9 | ||
| P/B | 0.85 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.52 |
EPS(TTM)2.37
EY20.88%
EPS(NY)2.42
Fwd EY21.31%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY10.1%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.22 |
F-Score5
WACC5.15%
ROIC/WACC0.83
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.98%
EBIT Next 3Y9.96%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.